Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs Tomivosertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Effector Therapeutics
- 04 Dec 2019 Planned End Date changed from 1 Dec 2019 to 1 Mar 2020.
- 04 Dec 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Mar 2020.
- 16 Jul 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Oct 2019.